Life Sciences Tools and Services
Company Overview of Ajinomoto Althea, Inc.
Ajinomoto Althea, Inc. operates as a contract development and manufacturing organization that provides clinical and commercial product development services. It offers aseptic drug product fill and finish services in the areas of formulation, aseptic vial filling, aseptic syringe filling, lyophilization, release testing, clinical packaging, and stability programs; biologics manufacturing services, such as upstream and downstream process development, and cGMP manufacturing (cGMP protein and DNA plasmid production), as well as a systems that provides pharmaceutical and biotechnology partners with peptides and protein biological products; protein analytics stability testing in the areas of analy...
11040 Roselle Street
San Diego, CA 92121
Founded in 1997
Key Executives for Ajinomoto Althea, Inc.
Chief Executive Officer and President
Chief Financial Officer and Senior Vice President
Senior Vice President of Operations
Director of Biologics Manufacturing
Compensation as of Fiscal Year 2014.
Ajinomoto Althea, Inc. Key Developments
Ajinomoto Althea Inc. Appoints J. David Enloe Jr. as President and Chief Executive Officer
Jan 6 14
Ajinomoto Althea Inc. announced the appointment of J. David Enloe Jr. as President and CEO. Mr. Enloe will be responsible for developing strategies to support the company's continued growth. Enloe brings over 20 years of executive management experience most of that in biotechnology, drug development, and GMP manufacturing management. Most recently, he served as the Head of the Viral Therapeutics Business Unit at Lonza AG. Mr. Enloe joined the team effective December 16, 2013. Dr. Hiroshi Shiragami and Dr. Magda Marquet will continue to serve Ajinomoto Althea Inc. as Co-Chairs of the board of directors.
Ajinomoto Althea, Inc. Presents at BioJapan 2013 World Business Forum, Oct-09-2013
Sep 25 13
Ajinomoto Althea, Inc. Presents at BioJapan 2013 World Business Forum, Oct-09-2013 . Venue: Pacifico Yokohama, Yokohama, Japan.
Althea Technologies & Profectus BioSciences Sign Manufacturing Agreement for Plasmid DNA Production
Feb 26 13
Althea Technologies, Inc. and Profectus BioSciences Inc. announced the signing of a manufacturing supply agreement for plasmid DNA production. Under the agreement, Althea will provide gram-scale quantities of cGMP (current Good Manufacturing Practice) manufactured plasmid DNA expressing IL-12 to assist Profectus Biosciences' ongoing DNA vaccine development efforts, which are supported by a contract from the National Institutes of Health. IL-12 helps prompt an immune response once the DNA enters a cell, which is part of Profectus Biosciences' technology platform designed to overcome the poor delivery and immunogenicity of many DNA vaccines.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|